Mohammad Hassan Sadeghi , Niloufar Kheradi , Shima Nazem , Soumayeh Amirsaadat , Maryam Ashourpour , Sara Aghakhani Chegeni , Sepideh Sohrabi , Maryam Zamani Sani , Ahmad Movahedpour , Elham Norouz Dolatabadi , Sajad Ehtiati
{"title":"Exosome biosensors for the detection of breast cancer","authors":"Mohammad Hassan Sadeghi , Niloufar Kheradi , Shima Nazem , Soumayeh Amirsaadat , Maryam Ashourpour , Sara Aghakhani Chegeni , Sepideh Sohrabi , Maryam Zamani Sani , Ahmad Movahedpour , Elham Norouz Dolatabadi , Sajad Ehtiati","doi":"10.1016/j.cca.2025.120456","DOIUrl":null,"url":null,"abstract":"<div><div>Breast cancer, the most common malignancy in women, is difficult to identify early with conventional techniques like biopsy and mammography, which are frequently invasive and prone to false negative results. Exosome-based detection is a novel, non-invasive diagnostic technique made possible by recent developments in biosensor technology. Exosomes, which are tiny extracellular vesicles released by cells, include biomarkers including microRNAs and oncogenic proteins that offer vital information about the occurrence and spread of breast cancer. By identifying exosomal biomarkers, biosensors use high sensitivity, specificity, and real-time analysis to facilitate early cancer detection, individualized treatment plans, and better patient outcomes. This review explores the biology of exosomes and their roles in intercellular communication, cancer progression, and therapeutic potential. It further examines the development and application of electrochemical, optical, and electrical biosensors for the detection of breast cancer-derived exosomes.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"577 ","pages":"Article 120456"},"PeriodicalIF":2.9000,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica Chimica Acta","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0009898125003353","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Breast cancer, the most common malignancy in women, is difficult to identify early with conventional techniques like biopsy and mammography, which are frequently invasive and prone to false negative results. Exosome-based detection is a novel, non-invasive diagnostic technique made possible by recent developments in biosensor technology. Exosomes, which are tiny extracellular vesicles released by cells, include biomarkers including microRNAs and oncogenic proteins that offer vital information about the occurrence and spread of breast cancer. By identifying exosomal biomarkers, biosensors use high sensitivity, specificity, and real-time analysis to facilitate early cancer detection, individualized treatment plans, and better patient outcomes. This review explores the biology of exosomes and their roles in intercellular communication, cancer progression, and therapeutic potential. It further examines the development and application of electrochemical, optical, and electrical biosensors for the detection of breast cancer-derived exosomes.
期刊介绍:
The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)
Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells.
The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.